menu
    • menu
    [{"orgOrder":0,"company":"AC Immune","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"ACI3024","moa":"Tau aggregates","graph1":"Neurology","graph2":"Phase I","graph3":"AC Immune","amount2":0.11,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.11,"dosageForm":"Oral","sponsorNew":"AC Immune \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"AC Immune \/ Eli Lilly"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Anti-TDP-43 antibody","moa":"TAR DNA binding protein 43","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Semorinemab","moa":"Tau protein","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"WuXi Biologics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2020","type":"Partnership","leadProduct":"Anti-TDP-43 antibody","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ AC Immune","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune \/ AC Immune"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2021","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Anti alpha-synuclein antibody","moa":"Alpha synuclein","graph1":"Neurology","graph2":"Preclinical","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Affiris","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2021","type":"Acquisition","leadProduct":"PD01","moa":"Alpha-synuclein","graph1":"Neurology","graph2":"Phase I","graph3":"AC Immune","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.10000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ AC Immune","highestDevelopmentStatusID":"6","companyTruncated":"AC Immune \/ AC Immune"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Semorinemab","moa":"Tau protein","graph1":"Neurology","graph2":"Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"8","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"pTau","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Crenezumab","moa":"Amyloid beta","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Crenezumab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ACI-24.060","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Not Applicable"},{"orgOrder":0,"company":"AC Immune","sponsor":"Worldwide Clinical Trials","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ACI-24.060","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Worldwide Clinical Trials","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Worldwide Clinical Trials"},{"orgOrder":0,"company":"AC Immune","sponsor":"Genentech","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Large molecule","year":"2024","type":"Termination","leadProduct":"Crenezumab","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"AC Immune","amount2":0.41999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0.41999999999999998,"dosageForm":"Infusion","sponsorNew":"AC Immune \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"AC Immune \/ Genentech"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2023","type":"Not Applicable","leadProduct":"ACI-35.030","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AC Immune","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"ACI-24.060","moa":"","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"AC Immune","amount2":2.2000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":2.2000000000000002,"dosageForm":"Injection","sponsorNew":"AC Immune \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"7","companyTruncated":"AC Immune \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2024","type":"Not Applicable","leadProduct":"JNJ-2056","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AC Immune","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"14","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"AC Immune","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Vaccine","year":"2024","type":"Licensing Agreement","leadProduct":"JNJ-2056","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"AC Immune","amount2":0.51000000000000001,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"AC Immune \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"14","companyTruncated":"AC Immune \/ Johnson & Johnson Innovative Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals by AC Immune

    Menu

    AC Immune

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JNJ-2056

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $509.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AC Immune Receives Second Milestone Payment For Progress in ACI-35.030 Phase 2b

                            Details : Through the license agreement, AC Immune is investigating active immunotherapy candidate JNJ-2056 (ACI-35.030) to treat patients suffering from preclinical (pre-symptomatic) Alzheimer’s disease.

                            Brand Name : ACI-35.030

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 17, 2024

                            Lead Product(s) : JNJ-2056

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : $509.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JNJ-2056

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AC Immune’s ACI-35.030 Granted FDA Fast Track Designation for Alzheimer’s Disease

                            Details : ACI-35.030 (JNJ-2056) is designed to enhance the formation of broad-spectrum protective antibodies against pTau being developed for Alzheimer’s Disease.

                            Brand Name : ACI-35.030

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            July 25, 2024

                            Lead Product(s) : JNJ-2056

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $2,200.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AC Immune and Takeda Sign Agreement for Alzheimer's Immunotherapy Targeting Amyloid Beta

                            Details : Under the agreement, Takeda will receive exclusive option to license global rights to ACI-24.060, a potential first-in-class, anti-Abeta active immunotherapy for Alzheimer’s disease.

                            Brand Name : ACI-24.060

                            Molecule Type : Vaccine

                            Upfront Cash : $100.0 million

                            May 13, 2024

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Takeda Pharmaceutical

                            Deal Size : $2,200.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crenezumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Genentech

                            Deal Size : $418.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            AC Immune to Regain Global Rights to Crenezumab and Semorinemab

                            Details : AC Immune regains global rights to anti-amyloid beta antibody RO5490245 (crenezumab) and anti-Tau antibody semorinemab, both evaluated for Alzheimer’s disease.

                            Brand Name : RO5490245

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 22, 2024

                            Lead Product(s) : Crenezumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Genentech

                            Deal Size : $418.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACI-35.030

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

                            Details : ACI-35.030 previously named as JNJ-64042056 is the first-in-class anti-pTau vaccine candidate which is being evaluated in phase 1/2 clinical trials for the treatment of Alzheimer’s Disease.

                            Brand Name : ACI-35.030

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            December 15, 2023

                            Lead Product(s) : ACI-35.030

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24.060, to Treat...

                            Details : ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, which is investigated for the treatment of Alzheimer’s Disease.

                            Brand Name : ACI-24.060

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            June 27, 2023

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Worldwide Clinical Trials

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and...

                            Details : ACI-24.060 is designed to enhance the formation of broad-spectrum protective antibodies having the potential to efficiently inhibit plaque formation and increase plaque clearance, and thereby may reduce or prevent disease progression.

                            Brand Name : ACI-24.060

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            January 26, 2023

                            Lead Product(s) : ACI-24.060

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ACI-35.030

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AC Immune’s Alzheimer’s Disease Vaccine-candidate ACI-35.030 Selected for Further Development

                            Details : Early clinical testing showed that ACI-35.030, a first-in-class anti-pTau vaccine, was generally well tolerated and induced specific activity against the pathological species of Tau, including the neurotoxic pTau and ePHF species, both of which are close...

                            Brand Name : ACI-35.030

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : ACI-35.030

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crenezumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AC Immune to Present Progress of Alzheimer’s Disease Programs targeting Abeta and Tau at the 15th CTAD ...

                            Details : MABT5102A (crenezumab) is a passive immunotherapy approach in which patients are treated with monoclonal antibodies that specifically recognize Aβ peptides. This humanized antibody uses an IgG4 backbone.

                            Brand Name : MABT5102A

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 23, 2022

                            Lead Product(s) : Crenezumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed

                            AC Immune

                            Switzerland arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Crenezumab

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Genentech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Detailed Data From the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alz...

                            Details : As previously reported, numerical differences favoring MABT5102A (crenezumab) over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistically significant.

                            Brand Name : MABT5102A

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 02, 2022

                            Lead Product(s) : Crenezumab

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Genentech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth